CRISPR Therapeutics AG (Nasdaq: CRSP) experienced a significant downturn on Friday, with shares plummeting 11.6% to close at $48.79, well below the opening price of $55.01. The sell-off occurred without any new company-specific announcements, as the most recent update on the investor relations page remains an April 7 conference listing. This decline underscores a shifting sentiment as the gene-editing pioneer transitions from a story of future potential to one of commercial execution.
Casgevy Revenue and Pipeline Progress
The company reported full-year 2025 revenue of $116 million for Casgevy, its first approved CRISPR therapy developed in partnership with Vertex Pharmaceuticals. In the fourth quarter alone, Casgevy generated $54 million. During 2025, 64 patients received infusions, while 147 initiated treatment with an initial cell collection, nearly tripling patient starts and collections compared to 2024. CEO Samarth Kulkarni highlighted steady progress across the pipeline, including Casgevy uptake, zugo-cel in autoimmune and cancer indications, and in vivo liver-editing projects.
Upcoming Shareholder Vote and Financial Position
Attention now turns to the June 4 annual general meeting in Zurich, where shareholders will vote on proposals to raise the company's capital band under Swiss law and carry forward a net loss of CHF 1.89 billion. CRISPR ended 2025 with $1.98 billion in cash, cash equivalents, and marketable securities, but losses are widening. The fourth-quarter net loss reached $130.6 million, up sharply from $37.3 million a year ago, while R&D spending climbed to $83.5 million for the quarter. In March, the company bolstered its balance sheet with an upsized $550 million convertible senior notes offering due in 2031, netting approximately $536.3 million, with an initial conversion price near $76.56 per share.
Analyst Divergence and Competitive Pressures
Market sentiment remains mixed. Of 19 analysts tracked by MarketBeat, 11 rate CRISPR as a buy or strong buy, six as hold, and two as sell, with an average price target of $64.53. Piper Sandler recently raised its target to $110 from $105, forecasting $300 million in Casgevy revenue from 150 patients in 2026. However, competitive pressures are mounting. Intellia Therapeutics announced plans to release top-line Phase 3 data from its HAELO trial of lonvoguran ziclumeran on April 27, the first-ever Phase 3 results for an in vivo CRISPR candidate, which could sway investor sentiment across the gene-editing sector.
Key Catalysts and Risks Ahead
CRISPR has a busy data calendar, with updates expected from its CTX310 Lp(a) program, CTX611 siRNA effort, zugo-cel, CTX340, and CTX460, most landing in the second half of the year. The revised Casgevy agreement places Vertex in charge of global development, manufacturing, and commercialization, with CRISPR receiving 40% of profits and costs. Rollout timing now depends heavily on Vertex's execution. Risks include a sluggish Casgevy rollout, delayed pediatric filings, or disappointing 2026 trial data, which could leave CRISPR with ample cash but no near-term second product. Friday's selloff sharpens the central question: Can Casgevy convert landmark approval into sustained commercial success?
